Data show that from 2013 to 2017, the size of China's ophthalmic diagnosis and treatment market increased from 46.
7 billion yuan to 86.
6 billion yuan, with an average annual compound growth rate of 16.
7%.
At present, with the rise in the incidence of eye diseases, the upgrading of ophthalmic treatment technology, and the improvement of patient diagnosis and treatment awareness, the scale of China's ophthalmic diagnosis and treatment market is growing rapidly, and some institutions predict that from 2020 to 2024, the compound annual growth rate of China's ophthalmic medical service market will be 11.
05%, and by 2024, the market size will reach 223.
1 billion yuan
In the context of the broad market prospects in the field of ophthalmic medicine, the field is attracting more and more pharmaceutical companies to enter the market
.
At the same time, a large number of innovative achievements have gradually begun to appear
.
It is understood that on September 25, Kelun Pharmaceutical announced that the chemical drug "brimonidine timolol eye drops" of the company's subsidiary, Jiangxi Kelun Pharmaceutical Co.
, Ltd.
, was recently approved by
the State Drug Administration for drug registration.
Public information shows that brimonidine timolol eye drops are a compound eye drops developed by Airgen to reduce elevated intraocular pressure in adults with open-angle glaucoma or high intraocular pressure
.
Kelun Pharmaceutical brimmonidine timolol eye drops is the first in China to be approved, and after the listing, it will provide domestic glaucoma patients with a drug choice
with both intraocular pressure reduction and optic nerve protection.
In addition to Kelun Pharmaceutical, many pharmaceutical companies have also taken the research and development of ophthalmic drugs as an important part of the company's strategic layout and are accelerating their layout
.
It is reported that Zhaoke Ophthalmology said in early August this year that its partner Vyluma Inc.
(a wholly-owned subsidiary of the American biopharmaceutical company Nevakar Inc.
) is conducting Phase III clinical trials of NVK002 (one of the core products of Zhaoke Ophthalmology) in Europe and the United States, which is expected to be completed by the end of 2022, and is expected to submit a new drug application to the US Food and Drug Administration in 2023.
NVK002 is currently positioned as the world's first clinically proven approved drug
to treat the deepening of myopia.
In July, Weiyan Biologics announced that its self-developed innovative drug VVN539 (for the treatment of open-angle glaucoma) completed the enrollment of the first patient in the United States Phase II clinical trial, marking the development of the first domestic independent innovative drug for glaucoma into a rapid promotion stage
.
In June, Oakon said that its pipeline core variety OT-401 (fluorine vitreous implantant) new drug marketing application (NDA) was officially approved by the State Food and Drug Administration (NMPA) for the treatment of chronic non-infectious uveitis (chronic NIU-PS)
involving the posterior segment of the eye.
In addition, Jixing Pharmaceutical also announced in April that it has introduced two in-research pre-research anti-eye therapeutics drugs developed by LENZ Therapeutics (a US-based biopharmaceutical company) in China with an advance payment of $110 million and a potential milestone payment
.
Industry analysts believe that driven by the popularity of electronic products and the aging of the population, the domestic ophthalmic drug market will continue to grow in the future due to the continuous expansion of the huge patient group and diagnosis and treatment needs, and the development space of the industry will become more and more broad
.
Affected by this, the R&D enthusiasm of pharmaceutical companies is expected to continue to rise, of which ophthalmic innovative pharmaceutical companies may become the darling of the capital market, and ophthalmology will gradually enter the era of
innovative drugs.
